Skip to main content

THE FIRST AND ONLY THERAPY TO TARGET IL-4Rα, THEREBY SPECIFICALLY INHIBITING IL-4 AND IL-13 SIGNALING1,2

Dual inhibition of IL-4 and IL-13 signaling may help1:

REDUCE TYPE 2
INFLAMMATION

REDUCE
ITCH

ACHIEVE
SUSTAINED REMISSION

The mechanism of dupilumab action has not been definitively established.

Type 2 cytokines such as IL-4 and IL-13 contribute to the development of the
itch and lesions of bullous pemphigoid3-10

aIL-4 acts on both type I and type II receptors to mediate type 2 inflammation.2

bType 2 cytokines (such as IL-4, IL-13, and IL-31) may also be produced by other immune cells, such as ILC2.11,12

IL-4 and IL-13 signaling help drive type 2 inflammation by
promoting Th2 response, driving Ig class switching, and
recruiting inflammatory CELLS3,8,9

DUPIXENT binds to IL-4
receptor alpha, inhibiting
IL-4– and IL-13–induced
inflammatory responses1,2

c Dimerization is when 2 protein subunits combine to form a larger complex. IL-4 signaling through type I receptor requires dimerization of the IL-4Rα with the gamma
chain. IL-4 or IL-13 signaling through type II receptor requires dimerization of IL-4Rα with IL-13Rα1.

IL-4 SIGNALING
(TYPE I RECEPTOR)

IL-4/IL-13 SIGNALING
(TYPE II RECEPTOR)

DO YOU HAVE PATIENTS WHO
MAY BE READY FOR DUPIXENT?

View case studies